Bevacizumab Concomitant with Pemetrexed for Patients with Advanced Non-small Cell Lung Cancer

Bevacizumab is a recombinant humanized monoclonal antibody used for multiple solid tumors in recent years, including lung cancer (Gentzler et al., 2013; Smith et al., 2013). At present, maintenance chemotherapy is a new perspective for advanced non-small cell lung cancer (NSCLC), which refers to the maintenance therapy in a certain period of induction chemotherapy to achieve the maximum tumor response, according to the additional chemotherapy which can prolong the survival time of patients by extending the total schedule of chemotherapy to achieve its higher total dose (Brattstorm et al., 2004; Akkuzu, 2012; Chen et al., 2012; Liu et al., 2012; Karayama et al., 2013; Alimujiang et al., 2013; Tai et al., 2013; Ugur et al., 2014). Therefore, this study aimed to explore whether bevacizumab concomitant with pemetrexed could provide benefits for patients with advanced cancers by observing their influence on the clinical efficacy, safety and survival time after first-line treatment of platinum-based chemotherapy in advanced NSCLC patients admitted in our hospital from May 2009 to May 2011.